Sign In
Last checked at 
1 Sep 2023 08:04
1 September 2023
RUA Life Sciences Plc
("RUA Life Sciences", the "Company" or the "Group")
Directorate Change
RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of Elast-Eon™, the world leading long-term implantable biostable polyurethane, announces that Iain Anthony, Director of Clinical and Regulatory Affairs has tendered his resignation from the Company in order to accept an opportunity elsewhere within the industry.
Iain joined RUA in November 2021 and has overseen the building of the Regulatory and Quality teams together with further development of the vascular graft device and was instrumental in undertaking the Q-Sub process with the FDA which has recently concluded succesfully.
Iain will step down from the board with immediate effect but will continue in his role as an employee for an appropriate handover period while the Board looks for his successor. The Board thanks Iain for his contribution to the business and wish him well.
For further information contact:
RUA Life Sciences
Bill Brown, Chairman Tel: +44 (0)1294 317073
Caroline Stretton, Group Managing Director Tel: +44 (0)1294 317073
Cenkos Securities plc (Nominated Adviser and Broker) Tel: +44 (0)20 7397 8900
Giles Balleny/Max Gould (Corporate Finance)
Michael Johnson (Sales)
About RUA Life Sciences
The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.
Our vision is to improve the lives of millions of patients by enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane. Whether it is licensing Elast-EonTM, manufacturing a device or component, or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.
Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.
The Group's four business units are:
RUA Contract Manufacture: | End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.
|
RUA Biomaterials: | Licensor of Elast-EonTM polymers to the medical device industry.
|
RUA Vascular: | Commercialisation of open surgical vascular grafts and patches
|
RUA Structural Heart: | Development of polymeric leaflet systems for heart valves. |
Follow the stocks
